Vertex Pharmaceuticals (VRTX) announced that the FDA has approved its next-in-class vanza triple therapy for treating people with cystic fibrosis (CF) aged six years and above. The drug will be marketed under the brand name Alyftrek.Post the FDA’s approval, the orally administered Alyftrek has been approved for use in CF patients aged six years and older who have at least one F508del mutation or another responsive mutation in the CF transmembrane conductance regulator (CFTR) gene responsive to the drug. The ...

Vertex Pharmaceuticals Inc VRTX last week announced that the Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR) had met its primary endpoint.The company announced that the FDA had approved Alyftrek (or vanzacaftor triple) in cystic fibroris (CF) six years and older, in-line with expectations, according to Goldman Sachs.Analyst Salveen Richter maintained a Buy rating for Vertex Pharmaceuticals and price target of $602.The Vertex Pharmaceuticals Thesis: During the initial launch of Alyft ...

Vertex Pharmaceuticals (VRTX 0.16%) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November. The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.But in recent weeks, Vertex stock has declined, and last week it lost nearly 12% in one trad ...

Shares of Vertex Pharmaceuticals Inc (NASDAQ:VRTX) are plummeting today, down 13% at $389.21, after the biotech company's non-opioid painkiller, Suzetrigine, matched the placebo in a phase 2 study. The stock is trading at 52-week lows after the news, earlier falling as low as $377.85, and headed for its worst single-day percentage loss since October 2020. Today's drop has VRTX breaking below support at the $445 level, which has been in place since early October, and dropping into negative territory for 2024 ...

Key TakeawaysVertex Pharmaceuticals shares sank Thursday after the company reported mixed results in a Phase 2 drug trial to treat lumbosacral radiculopathy (LSR), which causes leg and back pain.The company said the trial of suzetrigine met its primary endpoint in reducing pain, but a placebo reference arm also showed a "similar within-group reduction from baseline in pain."With Thursday's losses, Vertex shares fell into negative territory for the year. Vertex Pharmaceuticals (VRTX) shares sank Thursday mor ...

KING OF PRUSSIA, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) (“Vertex” or the “Company”), a global provider of tax technology solutions, has been named a Leader in three IDC MarketScape reports: IDC MarketScape: Worldwide SaaS and Cloud-Enabled SaaS Sales and Use Tax Automation Software for Enterprise 2024 Vendor Assessment (doc #US52035324, December 2024)IDC MarketScape: Worldwide Value-Added Tax Management Applications 2024 Vendor Assessment (doc #US52732824, December 2024)IDC Market ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Have you been paying attention to shares of Vertex (VERX) ? Shares have been on the move with the stock up 28.9% over the past month. The stock hit a new 52-week high of $55.52 in the previous session. Vertex has gained 104.7% since the start of the year compared to the 29.2% move for the Zacks Computer and Technology sector and the 34.2% return for the Zacks Internet - Software industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed ...